Optimization of LIPA targeting in Ovarian Cancer

San Antonio TX, February 06, 2026

Introducing ERX-208 – our supercharged ERX-41 analog for ovarian cancer!

Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher potency by engaging LIPA across a vastly larger interaction surface.

Link to paper;  https://lnkd.in/eJ2EJDRd